Global Cell Line Development Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, Primary Cell Lines), By Source (Mammalian Cell Line Development, Non Mammalian Cell Line Development), By Application (Drug Discovery, Research, Others), And By Geography - Forecasts From 2022 To 2027

Published:  Nov 2022 Report Code: KSI061612090 Pages: 140

The global cell line development market is projected to grow at a CAGR of 13.34% during the forecast period to reach US$6.239 billion by 2027, from US$2.596 billion in 2020.

A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space and is often used in place of primary cells to study biological processes. Cell line development refers to the process of developing stable cell lines for use in a number of important applications including biologics (e.g.recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of cell line development includes transfection and selection and single-cell cloning. Further, the global cell line development market is segmented into type, source, and geography.  

The growth of the global cell line development market is attributed to the rise in development and demand for monoclonal antibodies around the globe. The cell line development market will grow due to the rising demand for cell-based vaccines. The growing number of new virus outbreaks such as influenza, monkeypox, Ebola, and COVID-19 among others are contributing to the growing demand for cell-based vaccines. For instance, the World Health Organization’s Disease Outbreak News (DONs), which provided confirmed acute public health events of potential events of concern reported the first case of the Ebola virus in April 2022. The Ministry of Health of the Democratic Republic of the Congo declared the outbreak of the Ebola virus following a confirmed laboratory test of a 31-year-old male in the North-western Equateur province. Furthermore, Uganda also witnessed a confirmed 18 cases as of 25th September 2022 Ebola virus which were caused by Sudan Virus. Such increasing cases of infectious diseases and the growing risk of pandemics are the prime factors driving the demand for vaccines worldwide.

Moreover, in June 2022, just after a few months of recovery from the disruptions of the COVID-19 pandemic, the outbreak of monkeypox in different countries alarmed the vaccine developer companies to take measures to control the spread of the new virus. Further, many organizations are putting efforts to develop vaccines for the rising disease. For instance, the Centers for Disease Control and Prevention (CDC) mentions in its Vaccine considerations summary updated in September 2022, that the JYNNEOS vaccine is approved for the prevention of monkeypox and smallpox diseases. Further, the ACAM2000 Vaccines has been approved for immunization against smallpox which is made available for use against monkeypox under Expanded Access Investigational New Drug protocol, mentions the CDC.  As a result, the demand for vaccines is increasing globally, consequently increasing the demand for global cell line developments in the market and supporting the growth of the Global cell line development market during the anticipated period. 

In the global cell line development market, it is expected that the North American region is expected to hold a significant share during the forecast period.

 The rising research and development activities coupled with increasing investment in advanced processes and adoption of cell-based research in the countries like the US are driving the market in this region. Furthermore, the use of cell lines for biologics production, gene functional studies, and drug screening has further augmented the market’s growth in the North American region. Moreover, the continuous work on vaccine development by the pharmaceutical companies operating in this region and their ambitious plans to expand their geographic reach is anticipated to fuel market expansion in this region.

Product offering

  • KBI Biopharma offers mammalian cell line development can create mammalian protein expression systems by using cell line generation services like CHO-M Selexis SURE Technology. Furthermore, the company makes available both transient expression and stable pool generation approaches to aid proof-of-concept material generation for preclinical programs.
  • Fusion Antibodies Plc. can deliver a range of mammalian cell lines to offer confidence and flexibility in supporting the users’ clinical development. The company claims that it can cater to the requirement of rapid development of well-characterized mammalian cell lines with good clinical records.

COVID-19 Impact on the Cell Line Development Market

The pandemic had a positive impact on the Global cell line development market. The virus spread rapidly across the globe through transmission and took approximately a million deaths till January 2021. Major pharmaceutical companies and start-ups stepped forward to develop vaccines to combat the rising risk of COVID-19. Many organizations and companies pushed their efforts of research and development to develop vaccines and drugs against the coronavirus. Furthermore, government and world organizations provided funding to increase the research on vaccines for the deadly coronavirus, which further increased the demand for cell culture products, including Global cell line development products during the pandemic.

Global Cell Line Development Market Scope:

 

Report Metric Details
 Market Size Value in 2020  US$2.596 billion
 Market Size Value in 2027  US$6.239 billion
 Growth Rate  CAGR of 13.34% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Source, Application, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Lonza, Biofactura, WuXi AppTec, KBI Biopharma, ATUM, Fusion Antibodies plc, Selexis, In Vivo, Celonic AG, Merck KGaA
 Customization Scope  Free report customization with purchase

 

Market Segments

  • By Type
    • Recombinant Cell Lines
    • Hybridomas
    • Continuous Cell Lines
    • Primary Cell Lines
  • By Source
    • Mammalian Cell Line Development
    • Non-Mammalian Cell Line Development 
  • By Application
    • Drug discovery
    • Research
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the cell line development market size by 2027?
A1. The global cell line development market is projected to reach a market size of US$6.239 billion by 2027.


Q2. What is the size of the global cell line development market?
A2. Cell Line Development Market was valued at US$2.596 billion in 2020.


Q3. What are the growth prospects for the cell line development market?
A3. The cell line development market is projected to grow at a CAGR of 13.34% during the forecast period.


Q4. What factors are anticipated to drive the cell line development market growth?
A4. The cell line development market growth is attributed to the rise in development and demand for monoclonal antibodies around the globe.


Q5. Which region holds the largest share of the cell line development market?
A5. North American region is expected to hold a significant share of the cell line development market during the forecast period.


1. Introduction

1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

 

2. Research Methodology

2.1. Research Data

2.2. Assumptions

 

3. Executive Summary

3.1. Research Highlights

 

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. Global Cell Line Development Market, By Type

5.1. Introduction

5.2. Recombinant Cell Lines

5.3. Hybridomas

5.4. Continuous Cell Lines

5.5. Primary Cell Lines

 

6. Global Cell Line Development Market, By Source

6.1. Introduction

6.2. Mammalian Cell Line Development

6.3. Non-Mammalian Cell Line Development

 

7. Global Cell Line Development Market, By Application

7.1. Drug discovery

7.2. Research

7.3. Others

 

8. Global Cell Line Development Market, By Geography

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. Israel

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Others

 

9. Competitive Environment and Analysis

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrative

9.3. Mergers, Acquisition, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

 

10. Company Profiles

10.1. Lonza

10.2. Biofactura

10.3. WuXi AppTec

10.4. KBI Biopharma

10.5. ATUM

10.6. Fusion Antibodies plc

10.7. Selexis

10.8. In Vivo

10.9. Celonic AG

10.10. Merck KGaA

Lonza

Biofactura

WuXi AppTec

KBI Biopharma

ATUM

Fusion Antibodies plc

Selexis

In Vivo

Celonic AG

Merck KGaA

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us